USA flag logo/image

An Official Website of the United States Government

PARP-1 Inhibitors as Therapy for the Treatment of Stroke

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89423
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
NS062625
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
ANGION BIOMEDICA CORPORATION
51 Charles Lindbergh Blvd Uniondale, NY -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: PARP-1 Inhibitors as Therapy for the Treatment of Stroke
Agency: HHS
Contract: 1R43NS062625-01
Award Amount: $229,277.00
 

Abstract:

DESCRIPTION (provided by applicant): Stroke is leading cause of morbidity and mortality in the US. Research on the pathophysiological basis of stroke has produced new paradigms for prevention and treatment, but translation of these approaches into improved clinical outcomes has proved to be painfully slow. Preventive strategies focus primarily on reducing or controlling risk factors such as diabetes, hypertension, cardiovascular disease, and lifestyle; in patients with severe stenosis, carotid endarterectom y may be indicated. Cerebral angioplasty is used investigationally, but the high restenosis rates observed following coronary angioplasty suggest this approach may pose unacceptable risk for many patients. Therapeutic strategies focus primarily on acute tr eatment to reduce injury in the ischemic penumbra, the region of reversibly damaged tissue surrounding an infarct. Thrombolytic therapy has been shown to improve perfusion to the ischemic penumbra, but it must be administered within three hours of the onse t of infarction. However, new clinically useful agents must be efficacious when given at considerably longer intervals after the onset of ischemia as most stroke patients do not arrive for medical treatment but for several hours, much later than the short, efficacious window of other agents such as the thrombolytics. Targeting Poly (ADP-ribose) polymerase (PARP-1) in the setting of ischemic stroke may provide therapeutic benefit over a long time window, as studies have demonstrated that PARP-1 inhibition wi ll protect neuronal cells from the primary ischemic insult and also later when additional cells die as the result of the induced inflammatory response. PUBLIC HEALTH RELAVANCE: Stroke is leading cause of morbidity and mortality in the US. Research on the p athophysiological basis of stroke has produced new paradigms for prevention and treatment. Drugs that inhibit the enzyme, Poly (ADP- ribose) polymerase (PARP-1) in the setting of ischemic stroke may provide therapeutic benefit over a longer time window, as studies have demonstrated that PARP-1 inhibition will protect neuronal cells from the primary ischemic insult and also later when additional cells die as the result of the induced inflammatory response

Principal Investigator:

Business Contact:


igoldberg@angion.com
Small Business Information at Submission:

ANGION BIOMEDICA CORPORATION
ANGION BIOMEDICA CORP 1050 Stewart Ave. Garden City, NY 11530

EIN/Tax ID: 113430072
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No